Region: European Union

Health

Aiuto per i bambini malati: Accelerare l'approvazione di SRP-9001 (Elevidys) malattia muscolare #DMD

Kai Andre-Lüchtefeld

Petition is addressed to

Europäische Arzneimittel-Agentur (EMA)

37,552 Signatures

Petitioner did not submit the petition.

37,552 Signatures

Petitioner did not submit the petition.

Launched 2023
Collection finished
Submitted
Dialogue
Failed

To overview

statistics

37,552

Total signatures

30,184

Signatures from European Union

7,367

Signatures from other regions

1

Secret signature

Time course

117

Signatures per day on average

24.06.2024

Most signatures on the petition day

Connection to the topic. Which best describes you?

33%

feel responsible

33%

know someone who is affected

50%

help spread the word

50%

would participate in joint actions

Geographical distribution of signatures

by country

not assigned	7,135
Germany	23,425
Slovenia	3,376
Austria	998
Hungary	916
Belgium	729
Switzerland	421
Turkey	167
France	152
Kingdom of the Netherlands	141
Spain	92

by federal state

North Rhine-Westphalia	8,584
Lower Saxony	2,866
Baden-Württemberg	2,362
Bavaria	2,330
Hesse	1,293
Mecklenburg-Vorpommern	1,016
Saxony	846
Rhineland-Palatinate	840
Flemish Region	710
Schleswig-Holstein	598

To overview

Aiuto per i bambini malati: Accelerare l'approvazione di SRP-9001 (Elevidys) malattia muscolare #DMD

37,552 Signatures

Petitioner did not submit the petition.

37,552 Signatures

Petitioner did not submit the petition.

statistics

37,552

30,184

7,367

1

Time course

117

24.06.2024

Connection to the topic. Which best describes you?

33%

33%

50%

50%

Geographical distribution of signatures

by country

by federal state

You might also be interested in

Stop au réarmement européen

Non au portefeuille d'identité numérique de l'Union Européenne

Pour une IA qui améliore notre vie — Investissements publics massifs en Europe et pays partenaires

Help us to strengthen citizen participation. We want to support your petition to get the attention it deserves while remaining an independent platform.